Business
biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis
biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n \n biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis\n \n \nbiOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sep 4, 2014) - BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF)(TSX VENTURE:BTI), announces that the Natural Sciences and Engineering Research Council of Canada (\"NSERC\") has awarded a grant to the University of British Columbia (\"UBC\") in support of the university's collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis' extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier (\"BBB\") for the potential treatment of previously untreatable Central Nervous System (\"CNS\") diseases and conditions.\n The NSERC Collaborative Research & Development matching fund grant will extend for up to five years, pending continued industry support, with a total value of up to $750,000. The grant commences immediately with the aim of further optimizing the BBB shuttling technology owned by biOasis Technologies Inc., initially for the application to clinical treatment of Lysosomal Storage Diseases (\"LSDs\"). \n The award is intended to help expand the collaborative work between biOasis Technologies Inc. and UBC researcher Professor Wilfred Jefferies of the Michael Smith Laboratories. The proposed R&D is based on Dr. Jefferies' original discovery of a protein molecule that allows therapeutics such as lysosomal enzymes to cross the BBB and enter the brain.\n The BBB is formed by the brain capillary endothelium and prevents large-molecule neurotherapeutics and most small-molecule drugs from entering the brain. As a result, many diseases in the brain are untreatable. Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to the effective treatment of most brain disorders. \n LSD's are a group of more than fifty distinct diseases that cause physiological and neurological deterioration, predominantly in children. An LSD develops when a particular enzyme is missing or produced in insufficient quant...